Updated PIVOT data seem to support recent AUA/ASTRO/SUO guidelines

A new article in this week’s New England Journal of Medicine has given us follow-up data from the PIVOT trial of radical prostatectomy vs. simple observation in treatment of localized prostate cancer. … READ MORE …

Eighth randomized clinical trial of hypofractionated radiation therapy

We now have data from an eighth randomized clinical trial of hypofractionated radiation therapy. There are no surprises: … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …

Early chemotherapy in treatment of high-risk and aggressive prostate cancers?

So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …

Body mass index, surgery, and risk for prostate cancer-specific death

It is well understood that there is an association between obesity and future risk for prostate cancer-specific mortality among cancer-free men. What has not been so clear is the relationship between obesity and long-term outcomes, post-treatment, among men diagnosed early with localized disease … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

Patient-reported outcomes and quality of life in the ProtecT trial

We have already commented on the oncologic outcomes of patients enrolled in the ProtecT trial and published in today’s issue of the New England Journal of Medicine. In this commentary we shall comment on the separate paper that addresses patient-reported outcomes from that trial. … READ MORE …